PTPN2 Inhibitor (ZE00-0388 / Clinical Candidate)
Cancer Immunotherapy (specific indications not disclosed)
Pre-clinicalActive
Key Facts
Indication
Cancer Immunotherapy (specific indications not disclosed)
Phase
Pre-clinical
Status
Active
Company
About Mondego Bio
Mondego Bio is a private, preclinical-stage biotech developing novel oral PTPN2 inhibitors to overcome resistance in cancer immunotherapy. The company's lead candidate, ZE00-0388, has demonstrated strong target inhibition, high selectivity, and promising efficacy in preclinical models, leading to the selection of a clinical candidate in late 2025. Backed by a syndicate of top-tier life science investors including Biovance Capital, OrbiMed, and Torrey Pines, Mondego is targeting the initiation of first-in-human clinical trials in the first half of 2026.
View full company profile